CClinicalTrials.gg
WithdrawnNCT02506010Updated Oct 18, 2016

Accuracy Validation of a Pulse Oximetry Monitor

An observational study in Healthy, sponsored by Medtronic - MITG. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-18.

Sponsored by Medtronic - MITG · Observational

Why this study was withdrawn
Sponsor decided not to run this study.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to conduct an oxygen saturation (SpO2) accuracy validation comparing prototype pulse oximeter oxygen saturation measurements directly to arterial blood saturation during non-motion conditions over the range of 60-100% SaO2 as measured by Reference CO-Oximetry. Additionally, the prototype pulse oximeter pulse rate measurements will be compared to 3-lead ECG heart rate measurements made via a multi-parameter monitor.

Read the detailed description

The description of this study is to conduct an oxygen saturation (SpO2) accuracy validation comparing prototype pulse oximeter oxygen saturation measurements directly to arterial blood saturation during non-motion conditions over the range of 60-100% SaO2 as measured by Reference CO-Oximetry. Additionally, the prototype pulse oximeter pulse rate measurements will be compared to 3-lead ECG heart rate measurements made via a multi-parameter monitor.

02

Conditions studied

  • Healthy

Keywords

  • Hypoxia
03

In context

Lead sponsor

Medtronic - MITG is the lead sponsor of 176 studies on the registry; 5 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 17 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be ten to fifteen male and female subjects of any race, ranging in pigmentation from light to dark to meet the study design requirements

Inclusion criteria

  • healthy
  • non-smoking, or who have refrained from smoking for 2 days
  • male or female of any race
  • 18-45 years.
  • Subjects must have the ability to understand and provide written informed consent as well as be willing to comply with study procedures.
  • To be eligible to participate in the study, the subject must clear a recent physical (12-lead ECG, medical history and blood test for sickle cell disease.) prior to enrollment

Exclusion criteria

Exclusion Criteria:

    • morbid obesity (defined as BMI > 39.5),
  • injuries, deformities or abnormalities or piercings that may prevent proper application of the device under test, compromised circulation,
  • subjects with known respiratory conditions (smokers with COHb levels >3%, flu, pneumonia, bronchitis, shortness of breath/ respiratory distress, severe asthma, emphysema, COPD),
  • subjects with known heart or cardiovascular conditions (uncontrolled hypertension, heart arrhythmias other than sinus arrhythmia, previous heart attack, blocked artery, history of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy, history of stroke, transient ischemic attack or carotid artery disease),
  • other known health condition (diabetes, thyroid disease, kidney disease / chronic renal impairment, history of seizures (except childhood febrile seizures) or epilepsy, or unexplained syncope, recent history of frequent migraine headaches, recent head injury, cancer / chemotherapy
  • women actively trying to get pregnant or are pregnant,
  • clotting disorders (history of bleeding disorders or current use of blood thinners, Hemophilia, blood clots)
  • Sickle cell disease
  • Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • Unwillingness or inability to remove colored nail polish or artificial nails from test digit(s)
  • Prior or known allergies to: lidocaine (or similar pharmacological agents, e.g., Novocain) or heparin
  • Recent arterial cannulation (i.e., less than 30 days prior to study date), Six or more arterial cannulations of each (right \& left) radial artery, history of clinically significant complications from previous arterial cannulation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The OxiCable pulse rate measurement performance is an ARMS of 3 or better over the full range 60-100% SaO2.

    Time frame: 2.5 hours

07

Study locations

1 site
  • Clinimark
    Louisville, Colorado 80027, United States
08

References and documents

Individual participant data

Plan to share: Undecided — This study was cancelled.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02506010
Lead sponsor
Medtronic - MITG
Collaborators
Clinimark, LLC
Responsible party
Sponsor
First posted
Jul 22, 2015
Start date
Nov 2016
Primary completion
Jan 2017 (estimated)
Completion
Jan 2017 (estimated)
Last update
Oct 18, 2016

Study contacts

David Ransom, MD
principal investigator · Clinimark, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion